Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607

Role for a bidentate ribonuclease in the initiation step of RNA interference

Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 5,018

A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

RNA interference is mediated by 21- and 22-nucleotide RNAsPreprint

Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,354

Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate

Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W., & Tuschl, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6877 · Cited by 1,469

Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding

Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369

Mutant p53 and ETS2, a Tale of Reciprocity

Martinez, L. A. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00035 · Cited by 26

Biochemical Dissection of RNA Silencing in Plants

Tang, G., & Zamore, P. D. (2004) · Humana Press eBooks · doi:10.1385/1-59259-750-5:223 · Cited by 26

Selective Silencing of Viral Gene E6 and E7 Expression in HPV-Positive Human Cervical Carcinoma Cells Using Small Interfering RNAs

Jiang, M., & Milner, J. (2004) · Humana Press eBooks · doi:10.1385/1-59259-848-x:401 · Cited by 26

siRNA: a potential tool for future breast cancer therapy?

Størvold, G. L., Andersen, T., Perou, C., & Frengen, E. (2006) · Critical reviews in oncogenesis · doi:10.1615/critrevoncog.v12.i1-2.70 · Cited by 24

A rapid and sensitive assay for quantification of siRNA efficiency and specificity

Smart, N., Scambler, P. J., & Riley, P. R. (2005) · Biological Procedures Online · doi:10.1251/bpo99 · Cited by 25

Suppression of keratoepithelin and myocilin by small interfering RNAs (siRNA) in vitro.

Yuan, C., Zins, E. J., Clark, A. F., & Huang, A. (2007) · PubMed · Cited by 25

siRNA as a route to new cancer therapies

Ameyar‐Zazoua, M., Guasconi, V., & Ait‐Si‐Ali, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.2.221 · Cited by 23

Epigenetic manipulation of gene expression

Juliano, R. L., Dixit, V., Kang, H. M., Kim, T. Y., Miyamoto, Y., & Xu, D. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501053 · Cited by 25

RNA interference: ready to silence cancer?

D, S. M. M., Costa, R., & Nitti, D. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0709-6 · Cited by 23

Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53

Katkoori, V. R., Manne, K., Vital-Reyes, V. S., Rodríguez-Burford, C., Shanmugam, C., Sthanam, M., Manne, U., Chatla, C., Abdulkadir, S., & Grizzle, W. E. (2012) · Biotechnic & Histochemistry · doi:10.3109/10520295.2012.724713 · Cited by 22

MDM2 promotes cell motility and invasiveness through a RING‐finger independent mechanism

Polański, R., Warburton, H. E., Ray‐Sinha, A., Devling, T., Pakula, H., Rubbi, C. P., Vlatković, N., & Boyd, M. T. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.10.049 · Cited by 22

Advancements in p53-Based Anti-Tumor Gene Therapy Research

Peng, Y., Bai, J., Wang, L., Su, Z., & Cheng, X. (2024) · Molecules · doi:10.3390/molecules29225315 · Cited by 20

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets

Saâda-Bouzid, E., & Tourneau, C. L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00074 · Cited by 21

Genetic screening for Peutz–Jeghers syndrome

Ballhausen, W. G., & Günther, K. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.4.471 · Cited by 21

TP53 in Myelodysplastic Syndromes

Jiang, Y., Gao, S., Soubise, B., Douet‐Guilbert, N., Liu, Z., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13215392 · Cited by 22

Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A

Mook, O. R. F., Baas, F., de Wissel, M. B., & Fluiter, K. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2008.104 · Cited by 20

SiRNA based strategies for inhibition of apoptotic pathways in vivo—analytical and therapeutic implications

Zender, L., & Kubicka, S. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000012121.52210.23 · Cited by 20

TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug

Gheidari, F., Bakhshandeh, B., Teimoori‐Toolabi, L., Mehrtash, A., Ghadir, M., & Zeinali, S. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000118 · Cited by 19

Control of Nucleotide Metabolism Enables Mutant p53’s Oncogenic Gain-of-Function Activity

Schmidt, V. A., Nagar, R., & Martinez, L. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122759 · Cited by 20

Comparative studies of suppression of malignant cancer cell phenotype by antisense oligo DNA and small interfering RNA

Hiroi, N. F., Funahashi, A., & Kitano, H. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700869 · Cited by 18

Inhibition of Proliferation and Induction of Apoptosis in Human Renal Carcinoma Cells by Anti-telomerase Small Interfering RNAs

Zheng, J., Sun, Y., Pei, D., Liu, J.-J., Chen, J., Li, W., Sun, X., Shi, Q.-D., Han, R., & Teng-xiang, M. (2006) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2006.00182.x · Cited by 17

RNAi technology: A Revolutionary tool for the colorectal cancer therapeutics

Lv, W. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i29.4636 · Cited by 18

Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53

Marques, M. A., de Andrade, G. C., Silva, J. L., & de Oliveira, G. A. P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.944955 · Cited by 16

RNA interference as a potential tool in the treatment of leukaemia

Borkhardt, A., & Heidenreich, O. T. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.12.1921 · Cited by 17

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases

Ulanova, M., Schreiber, A. D., & Befus, A. D. (2006) · BioDrugs · doi:10.2165/00063030-200620010-00001 · Cited by 16

Variations of the 3′ Protruding Ends in Synthetic Short Interfering RNA (siRNA) Tested by Microinjection in Drosophila Embryos

Boutla, A., Delidakis, C., Livadaras, I., & Tabler, M. (2003) · Oligonucleotides · doi:10.1089/154545703322616970 · Cited by 16

Designing siRNA that distinguish between genes that differ by a single nucleotide

Schwarz, D. S., Ding, H., Kennington, L. A., Moore, J. T., Schelter, J. M., Burchard, J., Linsley, P. S., D, N. A. M., Xu, Z., & Zamore, P. D. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0020140.eor · Cited by 15

Small Interfering RNA for Effective Cancer Therapies

Wang, X., Chen, Y., Ren, J., & Qu, X.-H. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711794519528 · Cited by 14

Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3′‐UTR microRNA

Zhang, J., Huang, S., Zhang, H., Wang, H., Guo, H., Qian, G., Fan, X., Lu, J., Hoffman, A. R., Hu, J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24821 · Cited by 13

Suppression of Survivin Expression by Short Hairpin RNA Induces Apoptosis in Human Laryngeal Carcinoma Cells

Chen, X.-M., Luan, X., Lei, D., Ma, X., Liu, X., Liu, J., & Pan, X.-L. (2008) · ORL · doi:10.1159/000124290 · Cited by 13

A novel strategy for cancer gene therapy: RNAi

Pan, Q., Cai, R., Liu, X., & Qian, C. (2006) · Chinese Science Bulletin · doi:10.1007/s11434-006-1145-x · Cited by 13

Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer

LIU, Y., Tao, X., Fan, L., Jia, L., Gu, C., & Feng, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1065 · Cited by 12

Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

Brown, D. W., Beatty, P. H., & Lewis, J. D. (2022) · Cancers · doi:10.3390/cancers14215176 · Cited by 13

Targeting Oncogenes with siRNAs

Heidenreich, O. T. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-547-7_11 · Cited by 12

mRNA Processing and Metabolism

Schoenberg, D. R. (2004) · Humana Press eBooks · doi:10.1385/1592597505 · Cited by 11

DNA repair investigations using siRNA

Miller, H., & Grollman, A. P. (2003) · DNA repair · doi:10.1016/s1568-7864(03)00042-9 · Cited by 11

Silencing unhealthy alleles naturally

Moss, E. G. (2003) · Trends in biotechnology · doi:10.1016/s0167-7799(03)00088-x · Cited by 11

Gene Silencing Therapy Against Cancer

Song, C.-Z. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-222-9_11 · Cited by 10

Individualised cancer therapeutics: dream or reality?

Senzer, N. N., Shen, Y., Hill, C., & Nemunaitis, J. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.6.1189 · Cited by 10

The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges

Shao, Y., Ma, L., Zhang, T., Xu, T., Ye, Y., & Liu, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828162217 · Cited by 11

Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases

Farhat, M., Poissonnier, A., Hamzé, A., Ouk, C., Brion, J., Alami, M., Feuillard, J., & Jayat‐Vignoles, C. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.150 · Cited by 9

Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers

Zhang, N., Jing, Z., Song, J., Liang, Q., Xu, Y., Xu, Z., Wen, L., & Wei, P. (2025) · Biomolecules · doi:10.3390/biom15060763 · Cited by 11

Correlation between low-level expression of the tumor suppressor gene TAp73 and the chemoresistance of human glioma stem cells

Hu, X., Wu, N., Xia, P., Yu, S., Sun, F., & Chen, J. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1823-0 · Cited by 8

Emerging Approaches for Enabling RNAi Therapeutics

Mallick, A. M., Tripathi, A., Mishra, S., Mukherjee, A., Dutta, C., Chatterjee, A., & Roy, R. S. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200451 · Cited by 8

Personalized Cancer Approach: Using RNA Interference Technology

Nemunaitis, J. J., Rao, D. D., Liu, S., & Brunicardi, F. C. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-1100-0 · Cited by 8

Advances in RNA therapeutics for modulation of ‘undruggable’ targets

Martinsen, E., Jinnurine, T., Subramani, S., & Rogne, M. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.003 · Cited by 7

Advances in Therapeutic Approaches Using RNA Interference as a Gene Silencing Tool

Kaymaz, B. T., & Kosov, B. (2013) · Advanced Techniques in Biology & Medicine · doi:10.4172/2379-1764.1000108 · Cited by 7

Identification of a HSP40 gene involved in planarian regeneration

Ma, K.-X., Zhang, H.-C., Zhang, Y., Song, G., Wu, M., & Chen, G. (2017) · Biologia · doi:10.1515/biolog-2017-0157 · Cited by 7

Selective RNAi-mediated inhibition of mutated c-kit.

Ruano, I., & Izquierdo, M. (2009) · PubMed Central · Cited by 6

RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application

Kalavrizioti, D., Vourekas, A., Stamatopoulou, V., Toumpeki, C., Giannouli, S., Stathopoulos, C., & Drainas, D. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778194253 · Cited by 6

RNA interference and its therapeutic potential

Ghosal, A., Kabir, A. H., & Mandal, A. (2011) · Open Medicine · doi:10.2478/s11536-011-0005-5 · Cited by 5

Gene Therapy for Head and Neck Squamous Cell Carcinoma Using KITENIN (KAI1 COOH-Terminal Interacting Tetraspanin)-Antisense Therapy

Lee, J. K., Lee, D.-H., Sun, E. G., Bae, J. A., Lim, S. C., Min, J. J., Sung, M., & Kim, K. K. (2011) · Yonsei Medical Journal · doi:10.3349/ymj.2011.52.3.463 · Cited by 5

An Artificial CTCF Peptide Triggers Efficient Therapeutic Efficacy in Ocular Melanoma

Wen, X., Wang, H., Chai, P., Fan, J., Zhang, X., Ding, T., Jia, R., Ge, S., Zhang, H., & Fan, X. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.07.004 · Cited by 5

shRNA Expression Constructs Designed Directly from siRNA Oligonucleotide Sequences

Barøy, T., Sørensen, K., Lindeberg, M. M., & Frengen, E. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9247-8 · Cited by 5

In vivo depletion of T lymphocyte-specific transcription factors by RNA interference

Tesnière, A., Abermil, N., Schlemmer, F., Casares, N., Kepp, O., Péquignot, M. O., Michaud, M., Martins, I., Senovilla, L., Zitvogel, L., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.14.12256 · Cited by 5

Oncolytic viral therapy for human cancer: Challenges revisited

Tong, A. W. (2005) · Drug Development Research · doi:10.1002/ddr.20058 · Cited by 5

Cancer Gene Suppression Strategies: Issues and Potential

Passioura, T., & Symonds, G. P. (2004) · Current Issues in Molecular Biology · doi:10.21775/cimb.006.089 · Cited by 4

Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions

Naeimzadeh, Y., Tajbakhsh, A., & Fallahi, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26260 · Cited by 5

Attenuation of telomerase activity by siRNA targeted telomerase RNA leads to apoptosis and inhibition of proliferation in human renal carcinoma cells

Wen, R., Liu, J., Li, W., Yang, W., Mao, L., & Zheng, J. (2006) · Chinese Journal of Clinical Oncology · doi:10.1007/s11805-006-0097-x · Cited by 4

SiRNA Mediated Gene Silencing: A Mini Review

Joseph, B., Ajisha, S. U., & Jeevitha, M. V. (2012) · Aceh International Journal of Science and Technology · doi:10.13170/aijst.1.3.140 · Cited by 4

Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers

Xie, Z., Chng, W. J., Tay, K.-G., Liu, S. C., Zhou, J., & Chen, C.-S. (2010) · Biotechnology Letters · doi:10.1007/s10529-010-0423-5 · Cited by 4

Suppression of keratoepithelin and myocilin by small interfering RNA (an American Ophthalmological Society thesis).

Huang, A. (2007) · PubMed Central · Cited by 4

Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis

Ruano, I., Gargini, R., & Izquierdo, M. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07918.x · Cited by 3

RNAi as a novel therapeutic platform technology for oncological solutions

Shafi, G., Jamil, K., Kapley, A., Purohit, H. J., & Vamsy, M. (2009) · Biotechnology and Molecular Biology Reviews · doi:10.5897/bmbr2009.0010 · Cited by 3

Delivering siRNA in vivo for functional genomics and novel therapeutics

Lu, P. Y., & Woodle, M. C. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511546402.025 · Cited by 3

Oligonucleotide based-strategies for allergy with special reference to siRNA

Suzuki, M., Zheng, X., Zhang, X., Ichim, T. E., Beduhn, M., & Min, W. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902841924 · Cited by 2

ER-targeted Intrabodies Mediating Specific In Vivo Knockdown of Transitory Proteins in Comparison to RNAi

Backhaus, O., & Böldicke, T. W. (2016) · InTech eBooks · doi:10.5772/62103 · Cited by 2

Yeast Genetic Manipulation

Stewart, G. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-69126-8_16 · Cited by 2

Non-Saccharomyces (and Bacteria) Yeasts That Produce Ethanol

Stewart, G. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-69126-8_17 · Cited by 2

Caractérisation génomique des carcinomes épidermoïdes de la tête et du cou : impact et enjeux pour la prise en charge thérapeutique

Saâda-Bouzid, E., Milano, G. A., & Thariat, J. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.05.011 · Cited by 2

Drug resistance, and the role of p53, in lung cancer cell lines

Breen, L. (2005) · Arrow@dit (Dublin Institute of Technology) · Cited by 2

Tumor‐Selective Gene Therapy: Using Hairpin DNA Oligonucleotides to Trigger Cleavage of Target RNA by Endogenous flap endonuclease 1 (FEN 1) Highly Expressed in Tumor Cells

Wang, C., Wang, C., Xiao, C., Zhang, W., Guo, Y. H., Qu, M., Song, Q., Qi, X., & Zou, B. (2025) · Small · doi:10.1002/smll.202410146 · Cited by 1

Single domain antibodies for the knockdown of cytosolic and nuclear proteins

Böldicke, T. W. (2017) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899-c1-035 · Cited by 1

siRNA Targeting PDE5A Partially Restores Vascular Damage Due to Type 1 Diabetes in a Streptozotocin-Induced Rat Model

García-Rubio, V. G., Cabrera‐Becerra, S. E., Ocampo-Ortega, S. A., Blancas-Napoles, C. M., Sierra-Sánchez, V. M., Romero‐Nava, R., Gutiérrez-Rojas, R. A., Huang, F., Hong, E., & Villafaña, S. (2023) · Scientia Pharmaceutica · doi:10.3390/scipharm91040052 · Cited by 1

Genetische Grundlagen der Kanzerogenese

Bartram, C. R. (2009) · Springer eBooks · doi:10.1007/978-3-540-79725-8_4 · Cited by 2

Apoptosis Control Based on Down-Regulating the Inhibitor-of-Apoptosis (IAP) Proteins: Xiap Antisense and Other Approaches

LaCasse, E. C. (2004) · Cell engineering · doi:10.1007/1-4020-2217-4_10 · Cited by 1

Pharmacology and Emerging Clinical Application of RNA

Barik, S., & Bitko, V. (2006) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200400102 · Cited by 1

RNA Interference: The Next Gene‐Targeted Medicine

Oleinikov, A. V., & Gray, M. D. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse324 · Cited by 1

Effect of down-regulating VEGF on proliferation of colon carcinoma cell HT-29

Zhang, X., Ge, Y., Wang, H., Cao, M., Zhang, J., Zhang, Z., & Wang, X. (2007) · Frontiers in Biology · doi:10.1007/s11515-007-0006-6 · Cited by 1

The p53 Transcription Factor as Therapeutic Target in Cancer

Asker, C., Bykov, V. J. N., Méndez‐Vidal, C., Selivanova, G., Wilhelm, M., & Wiman, K. G. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18932-6_7 · Cited by 1

RNA interference gene therapy: Allelic gene inactivation: pinpointing the problem

Kolfschoten, I., & Agami, R. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302145 · Cited by 1

Genetische Grundlagen der Kanzerogenese

Bartram, C. R. (2004) · Springer eBooks · doi:10.1007/978-3-662-06670-6_4 · Cited by 1

Gene-Based Therapies for Lung Cancer

Nemunaitis, J. J., & Roth, J. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-524-8_14 · Cited by 1

Genome Scanning by RNA Interference

Beijersbergen, R. L., & Steinbach, O. C. (2010) · Wiley eBooks · doi:10.1002/9780470923733.ch4

DEVELOPING GENETICALLY ENGINEERED ONCOLYTIC VIRUSES FOR CANCER GENE THERAPY

Parviainen, S. (2015) · Työväentutkimus Vuosikirja

Endogenous Small RNAs in the Drosophila Soma: A Dissertation

Ghildiyal, M. (2010) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/d5wh-6e69

RNA ‐Based Therapies

Pascolo, S. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse028

Biochemical Mechanism of RNA Interference in Higher Organisms: A Dissertation

Schwarz, D. S. (2005) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/bzkt-qt51

Functional characterisation of microRNA-containing Argonaute protein complexes

Weinmann, L. (2009) · doi:10.5282/edoc.10324

Small interfering RNA technology in pancreatic ductal epithelial cells: future cancer therapy

Chow, J. Y. C., Carethers, J. M., & Cho, C. H. (2008) · Journal of Organ Dysfunction · doi:10.1080/17471060701275354

Influence of p53 small double stranded RNA interference on hepatoma cell line SK-HEP-1

Cao, X.-Z., Zhu, M., Zhu, Z., Feng, F., Zhao, M.-L., Chen, Y., & Liu, X. (2005) · Chinese Journal of Cancer Research · doi:10.1007/s11670-005-0005-6

Significance of genetic instability in development and chemosensitivity of malignant tumors

Olasz, J. (2009) · Clinical and Experimental Medical Journal · doi:10.1556/cemed.3.2009.1.17

Emerging Clinical Applications and Pharmacology of RNA

Barik, S., & Bitko, V. (2012) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200400102.pub2

Development of nonviral gene delivery and of anti-gene reagents

Ge, R. (2007) · Figshare

The specificity of synthetic siRNAs

Weitzman, J. B. (2002) · Genome biology · doi:10.1186/gb-spotlight-20021030-01

siRNA ET microRNA : BIOGENESE, MECANISME ET FONCTIONS

Varna, M., & Artenie, V. (2007) · DOAJ (DOAJ: Directory of Open Access Journals)

APPLICATIONS OF RNA INTERFERENCE TECHNOLOGIES IN PHARMACEUTICAL FIELDS Review Article

Singha, M., Tiwari, M., Thakkar, R., Kumar, S., & Shah, C. U. (2012)

Review Development of new RNAi therapeutics

Liu, G., & Wong‐Staal, F. (2007)

Silencing of HER2 gene expression by small interfering RNAs

Flack, A. (2006) · NORA - Norwegian Open Research Archives

Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human

Ruano, I., & Gargini, R. (2009)

In Brief

(2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd1000

Research Highlights

(2002) · Nature reviews. Cancer · doi:10.1038/nrc959

Cancer therapeutic targeting using mutant–p53-specific siRNAs

Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50

Selective Inhibition of p53 Dominant Negative Mutation by shRNA Resulting in Partial Restoration of p53 Activity

Chen, E. I.-T., Wu, J., Su, W.-H., Wang, T., & Au, L. (2009) · doi:10.6136/jms.2009.29(4).179

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 576